melatonin has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has been shown to be highly effective in reducing oxidative damage in the central nervous system; this efficacy derives from its ability to directly scavenge a number of free radicals and to function as an indirect antioxidant." | 2.40 | Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. ( Cabrera, J; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 1999) |
| "Melatonin was administered (20 mg/kg) intraperitoneally to Group-M and Group-P + M twice a day for five days." | 1.72 | Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model. ( Agar, A; Aytac, G; Ozkan, A; Tanriover, G; Yildirim, S, 2022) |
| "Melatonin treatment attenuated the decrease in tyrosine hydroxylase in the striatum and abolished it in the substantia nigra." | 1.43 | Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease. ( Carriere, CH; Kang, NH; Niles, LP, 2016) |
| "Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NF-κB levels in experimental PD." | 1.40 | Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease. ( Agar, A; Aslan, M; Dilmac, S; Gemici, B; Kaya, Y; Ogut, E; Ozkan, A; Ozsoy, O; Tanriover, G; Yildirim, FB, 2014) |
| "Melatonin is a neurohormone secreted by the pineal gland, which has several important physiological functions." | 1.40 | Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. ( Andreatini, R; Barbiero, JK; Bassani, TB; Boschen, SL; da Cunha, C; Gradowski, RW; Lima, MM; Santiago, RM; Vital, MA; Zaminelli, T, 2014) |
| "Melatonin is a natural antioxidant and free radical scavenger that has been shown to effectively reduce cellular oxidative stress and protect mitochondrial functions in vitro." | 1.37 | Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. ( Lau, YS; Patki, G, 2011) |
| "Melatonin has been reported to be neuroprotective in the 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of PD." | 1.36 | Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. ( Cannon, JR; Greenamyre, JT; Tapias, V, 2010) |
| "Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin." | 1.35 | Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. ( Borah, A; Mohanakumar, KP, 2009) |
| "Melatonin treatment restored the rotenone-induced decrease in GSH level and changes in antioxidant enzyme (SOD and catalase) activities in the SN." | 1.34 | Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. ( Mohanakumar, KP; Saravanan, KS; Sindhu, KM, 2007) |
| "Melatonin was initially dissolved in dimethyl sulfoxide (DMSO), diluted to 16 microg/ml and then provided in the drinking water for 4 weeks." | 1.31 | Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. ( Morgan, WW; Nelson, JF, 2001) |
| " We found that the antioxidant melatonin (500 microg/kg bw) prevents cell death as well as the damage induced by chronic administration of MPTP measured as number of nigral cells, tyrosine hydroxylase levels, and several ultra-structural features." | 1.31 | Protective effect of melatonin in a chronic experimental model of Parkinson's disease. ( Antolín, I; del Brío, Mde L; Herrera, F; Martín, V; Mayo, JC; Rodríguez, C; Sainz, RM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Yildirim, S | 1 |
| Ozkan, A | 2 |
| Aytac, G | 1 |
| Agar, A | 2 |
| Tanriover, G | 2 |
| Jagota, A | 1 |
| Mattam, U | 1 |
| Yurchenko, EA | 1 |
| Menchinskaya, ES | 1 |
| Pislyagin, EA | 1 |
| Trinh, PTH | 1 |
| Ivanets, EV | 1 |
| Smetanina, OF | 1 |
| Yurchenko, AN | 1 |
| Singhal, NK | 2 |
| Chauhan, AK | 1 |
| Jain, SK | 2 |
| Shanker, R | 1 |
| Singh, C | 1 |
| Singh, MP | 2 |
| Zaitone, SA | 1 |
| Hammad, LN | 1 |
| Farag, NE | 1 |
| Yildirim, FB | 1 |
| Ozsoy, O | 1 |
| Kaya, Y | 1 |
| Ogut, E | 1 |
| Gemici, B | 1 |
| Dilmac, S | 1 |
| Aslan, M | 1 |
| Bassani, TB | 1 |
| Gradowski, RW | 1 |
| Zaminelli, T | 1 |
| Barbiero, JK | 1 |
| Santiago, RM | 1 |
| Boschen, SL | 1 |
| da Cunha, C | 1 |
| Lima, MM | 1 |
| Andreatini, R | 1 |
| Vital, MA | 1 |
| Naskar, A | 1 |
| Prabhakar, V | 1 |
| Singh, R | 1 |
| Dutta, D | 1 |
| Mohanakumar, KP | 3 |
| Carriere, CH | 1 |
| Kang, NH | 1 |
| Niles, LP | 1 |
| Talanov, SA | 2 |
| Sahach, VF | 2 |
| Tapias, V | 2 |
| Escames, G | 1 |
| López, LC | 1 |
| López, A | 1 |
| Camacho, E | 1 |
| Carrión, MD | 1 |
| Entrena, A | 1 |
| Gallo, MA | 1 |
| Espinosa, A | 1 |
| Acuña-Castroviejo, D | 1 |
| Cannon, JR | 1 |
| Greenamyre, JT | 1 |
| Borah, A | 1 |
| Timoshchuk, SV | 1 |
| Rudyk, OV | 1 |
| Arushanian, EB | 1 |
| Patki, G | 1 |
| Lau, YS | 1 |
| Srivastava, G | 1 |
| Agrawal, S | 1 |
| Coulom, H | 1 |
| Birman, S | 1 |
| Willis, GL | 2 |
| Robertson, AD | 2 |
| Singh, S | 1 |
| Ahmed, R | 1 |
| Sagar, RK | 1 |
| Krishana, B | 1 |
| Saravanan, KS | 1 |
| Sindhu, KM | 1 |
| Lin, CH | 1 |
| Huang, JY | 1 |
| Ching, CH | 1 |
| Chuang, JI | 1 |
| Reiter, RJ | 1 |
| Cabrera, J | 1 |
| Sainz, RM | 2 |
| Mayo, JC | 2 |
| Manchester, LC | 1 |
| Tan, DX | 1 |
| Lin, AM | 1 |
| Morgan, WW | 1 |
| Nelson, JF | 1 |
| Antolín, I | 1 |
| del Brío, Mde L | 1 |
| Herrera, F | 1 |
| Martín, V | 1 |
| Rodríguez, C | 1 |
3 reviews available for melatonin and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
[A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Topics: Cognition Disorders; Corpus Striatum; Dementia; Humans; Melatonin; Neuroprotective Agents; Nootropic | 2010 |
Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Melatonin; Neuroprotective Agents; Pa | 2012 |
Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism.
Topics: Alzheimer Disease; Animals; Cell Death; Drug Evaluation, Preclinical; Free Radical Scavengers; Free | 1999 |
1 trial available for melatonin and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Topics: 5-Methoxytryptamine; Animals; Behavior, Animal; Callithrix; Cross-Over Studies; Eating; Male; Melato | 2005 |
23 other studies available for melatonin and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model.
Topics: Animals; Male; Melatonin; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Parkinsonian Disorde | 2022 |
Daily chronomics of proteomic profile in aging and rotenone-induced Parkinson's disease model in male Wistar rat and its modulation by melatonin.
Topics: Age Factors; Aging; Animals; Biomarkers; Brain; Circadian Rhythm; Disease Models, Animal; Electropho | 2017 |
Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson's Disease Models.
Topics: Alkaloids; Animals; Antioxidants; Antiparkinson Agents; Aquatic Organisms; Aspergillus; Biological P | 2018 |
Silymarin- and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism.
Topics: Animals; Antioxidants; Apoptosis; Cell Cycle; Disease Models, Animal; Gene Expression Regulation; In | 2013 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; D | 2013 |
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
Topics: Animals; Antioxidants; Dopaminergic Neurons; Male; Melatonin; Motor Activity; Oxidopamine; Parkinson | 2014 |
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
Topics: Animals; Antidepressive Agents; Corpus Striatum; Dopamine; Male; Melatonin; Motor Activity; Neuropro | 2014 |
Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; D | 2015 |
Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Male; Melatoni | 2016 |
[Antioxidants prevent experimental hemiparkinsonism in rats].
Topics: Animals; Antioxidants; Behavior, Animal; Chromans; Disease Models, Animal; Dopamine; Male; Melatonin | 2008 |
Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice.
Topics: Animals; Calcium; Corpus Striatum; Cytosol; Electron Transport Complex I; Enzyme Induction; Kynurami | 2009 |
Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Topics: Animals; Body Weight; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Mel | 2010 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System | 2009 |
[An increased sensitivity of the mitochondrial permeability transition pore to calcium in the heart of rats with chronic deficiency of nigrostriatal dopamine].
Topics: Animals; Calcium; Chronic Disease; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hear | 2009 |
Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Free Radic | 2011 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanog | 2004 |
Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Topics: 5-Methoxytryptamine; Animals; Male; Melatonin; Naphthalenes; Oxidopamine; Parkinsonian Disorders; Ra | 2004 |
Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat.
Topics: Animals; Dopamine; Female; Melatonin; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Dis | 2006 |
Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
Topics: Animals; Catalase; Glutathione; Hydroxyl Radical; Male; Melatonin; Oxidative Stress; Parkinsonian Di | 2007 |
Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Down-Regul | 2008 |
Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats.
Topics: Anesthesia; Animals; Brain; Corpus Striatum; Deferoxamine; Dopamine; Drug Interactions; Glutathione; | 2001 |
Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 2001 |
Protective effect of melatonin in a chronic experimental model of Parkinson's disease.
Topics: Animals; Axons; Cell Death; Chronic Disease; Disease Models, Animal; DNA Fragmentation; Dose-Respons | 2002 |